phase III clinical study
Bolstered by the success of KRAS G12C inhibitors in lung cancer, smaller firms are developing drugs for a range of other KRAS-mutated cancers and trying to anticipate resistance.Â
Exelixis Launches Phase III Trial of XL092 in Certain Colorectal Cancer Patients
The firm will study XL092 plus Tecentriq in patients with microsatellite stable and mismatch repair-proficient tumors, and also consider RAS status.
Recursion Launches Clinical Trial for Targeted Drug in NF2-Mutated Meningioma Patients
The trial will pit Recursion's HDAC inhibitor REC-2282 against a placebo in patients with progressive meningiomas harboring NF2 mutations.
NICE Recommends Eli Lilly's Verzenio as Adjuvant Treatment for High-Risk, Early-Stage Breast Cancer
The agency recommended the CDK4/6 inhibitor plus hormone therapy for HR-positive, HER2-negative, early-stage breast cancer patients at high risk of recurrence.
Day One Bio Raises $150M in Public Offering of Common Stock
The funds will be used to support two ongoing Phase II clinical trials and to begin a Phase III study off its lead candidate tovorafenib in newly diagnosed pediatric glioma.